The combined ratio of estrogen, progesterone, Ki‐67, and P53 to predict the recurrence of endometrial cancer

Abstract Background and Objectives We aimed to explore the capacity of the combined ratio of biomarkers to predict the recurrence of Stage I–III endometrial cancer (EC). Methods A total of 473 patients were enrolled after screening. The cut‐off value of the ratio was calculated by the receiver operating characteristic curve (ROC). The univariate and multivariate Cox regression analysis was used to assess the correlation between the combined ratio and the recurrence of EC. The differences of clinicopathological parameters between the two groups divided based on the threshold were compared. Result The ROC curve showed that 0.92 was the optimal cut‐off value of the ratio ([ER + PR]/[P53 + Ki67]). The multivariate analysis demonstrated that only International Federation of Gynecology and Obstetrics stage ( p = .031) and the combined ratio ( p = .004) were independent risk factors of recurrence. The 3‐year recurrence‐free survival (RFS) and overall survival of patients in the low‐ratio group were 54.1% and 66.8%, respectively; while in the high‐ratio group were 94.9% and 97.9%, respectively ( p < .001). The 3‐year RFS of 194 patients, who did not receive the adjuvant therapy, was 54.7% and 97.2% between two groups ( p < .001). Conclusions The optimal cut‐off value (0.92) of the combined ratio was demonstrated to be better to predict the recurrence of EC than a single immunohistochemical marker.